Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy.

[1]  Manesh R. Patel,et al.  Rivaroxaban in Peripheral Artery Disease after Revascularization. , 2020, The New England journal of medicine.

[2]  Deepak L. Bhatt,et al.  Ticagrelor in Patients with Stable Coronary Disease and Diabetes. , 2019, The New England journal of medicine.

[3]  K. Mahaffey,et al.  Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial , 2018, Vascular medicine.

[4]  Jeroen J. Bax,et al.  The 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in Collaboration With the European Society for Vascular Surgery (ESVS). , 2018, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[5]  E. Vicaut,et al.  Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: The randomized AMERICA Study. , 2018, International journal of cardiology.

[6]  B. Lewis,et al.  Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE‐2 trial , 2018, American heart journal.

[7]  J. Bosch,et al.  Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2018, Lancet.

[8]  Khalid Yusoff,et al.  Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2017, Lancet.

[9]  Jeroen J. Bax,et al.  Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). , 2018, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[10]  Deepak L. Bhatt,et al.  Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria , 2017, European heart journal.

[11]  Deepak L. Bhatt,et al.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease , 2017, The New England journal of medicine.

[12]  J. Massaro,et al.  Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. , 2017, JACC. Cardiovascular interventions.

[13]  L. Fleisher,et al.  2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[14]  K. Mahaffey,et al.  Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Artery Disease , 2017, The New England journal of medicine.

[15]  A. J. O’Malley,et al.  Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization. , 2016, Journal of vascular surgery.

[16]  J. Cigarroa,et al.  2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, The Journal of thoracic and cardiovascular surgery.

[17]  Laura Mauri,et al.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[18]  Deepak L. Bhatt,et al.  Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. , 2016, Journal of the American College of Cardiology.

[19]  B. Modarai,et al.  Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis , 2015, PloS one.

[20]  K. Mahaffey,et al.  Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial , 2015, European journal of preventive cardiology.

[21]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[22]  Mario J. Garcia,et al.  Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. , 2015, Journal of the American College of Cardiology.

[23]  S. Windecker,et al.  Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. , 2015, JAMA.

[24]  Manesh R. Patel,et al.  Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). , 2014, American heart journal.

[25]  Marc P. Bonaca,et al.  Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke , 2013, Stroke.

[26]  Deepak L. Bhatt,et al.  Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. , 2012, The New England journal of medicine.

[27]  J. Ruidavets,et al.  Prognostic usefulness of clinical and subclinical peripheral arterial disease in men with stable coronary heart disease. , 2012, The American journal of cardiology.

[28]  Marc P. Bonaca,et al.  Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.

[29]  Giuseppe Ambrosio,et al.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. , 2012, The New England journal of medicine.

[30]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[31]  Deepak L. Bhatt,et al.  APPRAISE 2. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome for the APPRAISE-2 Investigators* , 2011 .

[32]  Deepak L. Bhatt,et al.  Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry , 2010, Vascular medicine.

[33]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[34]  Deepak L. Bhatt,et al.  Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry , 2009, European heart journal.

[35]  Deepak L. Bhatt,et al.  Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.

[36]  Deepak L. Bhatt,et al.  One-year cardiovascular event rates in outpatients with atherothrombosis. , 2007, JAMA.

[37]  F. Fowkes,et al.  Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. , 2006, European heart journal.

[38]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[39]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.

[40]  V. Aboyans,et al.  Subclinical peripheral arterial disease and incompressible ankle arteries are both long-term prognostic factors in patients undergoing coronary artery bypass grafting. , 2005, Journal of the American College of Cardiology.

[41]  Eric J Topol,et al.  Critical issues in peripheral arterial disease detection and management: a call to action. , 2003, Archives of internal medicine.

[42]  M. Criqui,et al.  Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care , 2001 .